Article
Treatment Extension of Pegylated Interferon Alpha and Ribavirin Does Not Improve SVR in Patients with Genotypes 2/3 without Rapid Virological Response (OPTEX Trial): A Prospective, Randomized, Two-Arm, Multicentre Phase IV Clinical Trial.
PloS one - 1 Jan 2015
Heidrich Benjamin, Cordes Hans-Jörg, Klinker Hartwig, Möller Bernd, Naumann Uwe, Rössle Martin, Kraus Michael R, Böker Klaus H, Roggel Christoph, Schuchmann Marcus, Stoehr Albrecht, Trein Andreas, Hardtke Svenja, Gonnermann Andrea, Koch Armin, Wedemeyer Heiner, Manns Michael P, Cornberg Markus
Abstract excerpt
UNLABELLED: Although sofosbuvir has been approved for patients with genotypes 2/3 (G2/3), many parts of the world still consider pegylated Interferon alpha (P) and ribavirin (R) as standard of care for G2/3. Patients with rapid virological response (RVR) show response rates >80%. However, SVR (sustained virological response) in non-RVR patients is not satisfactory. Longer treatment duration may be required but...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.